The decrease in HbA1c at 24 months (1.1%) observed here is similar to the targeted HbA1c reduction after 6 months of IDegAsp treatment in Japanese patients with T2D whose insulin levels were insufficiently controlled by previous therapies (1.4%) (16). This evidence concerns the gene INS and type 2 diabetes mellitus.